Intrafractional Vaginal Dilation in Anal Cancer Patients Undergoing Pelvic

Status Recruiting

Clinical Trial Summary

A commercially available vaginal dilator set will be used as measuring device. The grading of vaginal stenosis will be determined as difference of the diameter of vaginal dilator to the baseline. A reduction of the diameter of <20% is defined as vaginal stenosis Grade 1, a reduction of 20-35% as Grade 2, a reduction of >35-49% as Grade 3 and a reduction >/=50% as Grade 4. The investigators hypothesize that the rate of vaginal stenosis Grade 1 or higher 12 months after radiotherapy is lower in the group using extended vaginal dilation during radiotherapy (Arm A). Rates of vaginal stenosis of 50% have been observed in previous patient collectives and the investigators hypothesize that a reduction to 25% is possible in the experimental group.

Clinical Trial Description

The study is designed as a prospective, randomized, two-armed, single-center phase-II-trial. 60 patients will be included in the study. Patients fulfilling the inclusion criteria will be randomized into one of the two arms, which differ only in the diameter of a tampon used for vaginal dilatation during treatment. All patients will receive standard (chemo)radiotherapy with a total dose of 45-50,4 Gy (single dose 1,8-2 Gy) to the pelvic and inguinal (if required) lymphatic drainage with a boost to the anal canal up to 54-60 Gy (single doses 1.8-2.2 Gy). The primary objective is the assessment of the incidence and grade of vaginal fibrosis 12 months after (chemo)radiotherapy for anal cancer depending on the extent of intrafractional vaginal dilatation. Secondary endpoints are clinical symptoms and toxicity according to the Common Toxicity Criteria (CTC) version 5.0, assessment of clinical feasibility of daily use of a tampon for vaginal dilatation, assessment of the compliance for the use of a vaginal dilatator and quality of life assessed with the EORTC-QLQ30/-ANL27 questionnaires. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04094454
Study type	Interventional
Source	University Hospital Heidelberg
Contact	Nathalie Arians, MD
Phone	+49 6221 568202
Email	nathalie.arians@med.uni-heidleberg.de
Status	Recruiting
Phase	N/A
Start date	October 1, 2019
Completion date	October 2025

View Details

See also
Status	Clinical Trial	Phase
Enrolling by invitation	`NCT05060471` - PD-1 Blockade Combined With Chemotherapy Followed by Concurrent Immunoradiotherapy for Locally Advanced SCCA Patients	Phase 2
Active, not recruiting	`NCT02135419` - Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions	Phase 3
Completed	`NCT05518201` - Evaluate the Safety and Immunogenicity of a 9-valent HPV Vaccine in Chinese Healthy Male Aged 9-45 Year-old	Phase 1
Withdrawn	`NCT02857608` - A Prospective, Open-Label, Multi-center Comparison of Lymphoseek Identified Lymph Nodes and Clinically Identified Lymph Nodes of Subjects With Known Cancer of the Anus	Phase 2
Active, not recruiting	`NCT02546973` - Quality of Life in Patients With Anal Cancer
Terminated	`NCT00903396` - Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer	Phase 2
Completed	`NCT00550589` - Cidofovir in Treating HIV-Infected Patients With High-Grade Squamous Intraepithelial Lesions of the Skin Near the Anus	Phase 2
Terminated	`NCT00896467` - Psychological and Emotional Impact in Patients Undergoing Treatment For Metastatic Cancer Either in a Clinical Trial or as Standard Off-Trial Therapy	N/A
Completed	`NCT00324415` - Combined Modality Therapy for Patients With With HIV and Stage I, Stage II, or Stage III Anal Cancer	Phase 2
Terminated	`NCT00568425` - QOL & Functional Outcomes After Combined Modality Tx for Anal CA: Comparison of Conventional vs IMRT
Terminated	`NCT00267787` - Molecular Genetic and Pathological Studies of Anal Tumors
Completed	`NCT00066430` - Infrared Coagulation in Preventing Anal Cancer in Patients With HIV Who Have Anal Neoplasia	Phase 1
Completed	`NCT04083053` - High-Resolution Anoscopy Perceived Discomfort Study	N/A
Completed	`NCT03506529` - Identification of Predictive Factors for Physiological Hypermetabolism of the Anal Canal in 18F-FDG PET / CT
Recruiting	`NCT05835947` - Anal Cancer Risk In Women
Not yet recruiting	`NCT03947775` - HPV-SAVE_Merck_Sub-Study for Preventing Recurrence of HSIL	Phase 2
Recruiting	`NCT04857528` - Detecting HPV DNA in Anal and Cervical Cancers
Recruiting	`NCT04907643` - Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes	N/A
Recruiting	`NCT04708470` - A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers	Phase 1/Phase 2
Active, not recruiting	`NCT01937780` - Anal Cancer Radiotherapy Study

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Intrafractional Vaginal Dilation in Anal Cancer Patients Undergoing Pelvic Radiotherapy — DILANA

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms